# Effect of Enzalutamide Dose Reduction on Fatigue, Cognition, and Drug Trough Levels in Patients With Prostate Cancer

> **NCT03124615** · PHASE2 · UNKNOWN · sponsor: **Macquarie University, Australia** · enrollment: 47 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT03124615
- **Lead sponsor:** Macquarie University, Australia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-05
- **Primary completion:** 2020-12
- **Final completion:** 2021-06
- **Target enrollment:** 47 (ESTIMATED)
- **Last updated:** 2017-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03124615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03124615, "Effect of Enzalutamide Dose Reduction on Fatigue, Cognition, and Drug Trough Levels in Patients With Prostate Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03124615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*